Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer Appoints CSO | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Pfizer Appoints CSO

Isacson is a world-renowned neurology scientist

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dr. Ole Isacson has been appointed chief scientific officer of  Pfizer’s Neuroscience Research Unit and senior vice president, effective September 16. Dr. Isacson is a world-renowned scientist and Professor of Neurology at Harvard Medical School. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. Dr. Isacson will report to Mikael Dolsten, president of Worldwide R&D.

Dr. Isacson held a two-year postdoctoral fellowship at Cambridge University in England before joining Harvard in 1989. During the past 20 years, Dr. Isacson’s lab has become known as one of the most recognized academic research centers for Parkinson’s disease and other neurodegenerative disorders.

“Dr. Isacson’s deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer’s and Parkinson’s disease, where we are working to advance potential breakthrough therapies to fill the tremendous unmet need that exists for patients,” said Dr. Dolsten. “In addition, his strong ties in the local academic community will be important as our Cambridge site continues to drive collaborations with leading scientific and academic institutions that can help us speed the pace of discovery.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters